Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
36 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsFDA accepts Roche´s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
(WorldNews Switzerland)

 
 

25 february 2020 08:38:34

 
FDA accepts Roche´s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
(WorldNews Switzerland)
 


FDA accepts Roche`s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment US Food Drug and Administration is expected to decide on approval by 18 October 2020 Basel, 25 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company`s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with...


 
55 viewsCategory: General > Europe > Switzerland
 
Swiss Emergency Plan of Credit Suisse approved by FINMA
(WorldNews Switzerland)
Annual results as per 31 December 2019
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten